An ideal treatment for SK would have little to no pain, be able to treat numerous lesions, and present little risk of scarring and hyperpigmentation.The first and only medication FDA approved to treat SKs is Eskata (40% hydrogen peroxide, Aclaris), which …

2023年8月9日 · Eskata (40% hydrogen peroxide) was the first Food and Drug Administration (FDA)–approved topical treatment for seborrheic keratosis. Despite offering a promising balance between efficacy and side effects, Eskata was discontinued for distribution in the United States due to insufficient market acceptance by physicians and patients.

2021年9月7日 · A topical cosmetic cream with urea and hydroxy acids shows efficacy and tolerability in the treatment of patients with seborrheic keratoses, investigators reported in a study published in the Journal of Cosmetic Dermatology.

2017年12月15日 · Aclaris Therapeutics announced that the Food and Drug Administration (FDA) has approved Eskata (hydrogen peroxide) topical solution for the treatment of raised seborrheic keratoses. Eskata is a high-concentration hydrogen peroxide-based topical solution intended for application in office by a healthcare provider.

2023年3月22日 · DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication.

The FDA recently approved ESKATA, the first ever topical medication specifically for the treatment of seborrheic keratosis. ESKATA is comprised of a high level of hydrogen peroxide. This new development is exciting as it is a non-invasive way to treat these lesions.

2022年6月23日 · DermBiont’s Phase 2 adaptive design trial tested a 1% SM-020 Gel on four SK lesions in cohorts of five patients across three different treatment regimens: twice daily for 14 days, twice daily for 28 days, and pulse dosing for 28 days (four days on and four days off).

2017年12月20日 · ESKATA, a hydrogen peroxide-based topical solution, was developed by dermatologist-led biopharmaceutical company Aclaris Therapeutics. This isn't like your over-the-counter acne cream. According...

2018年9月12日 · Intended for in-office, dermatologist-applied use only, this 40 percent hydrogen peroxide topical solution is colorless and clear. It can be directly applied to a patient’s seborrheic keratosis using a pen-like applicator in two treatments approximately three weeks apart.